We are analyzing https://link.springer.com/article/10.1007/s00259-025-07123-3.

Title:
Exploring the landscape of current in vitro and in vivo models and their relevance for targeted radionuclide theranostics | European Journal of Nuclear Medicine and Molecular Imaging
Description:
Cancer remains a leading cause of mortality globally, driving ongoing research into innovative treatment strategies. Preclinical research forms the base for developing these novel treatments, using both in vitro and in vivo model systems that are, ideally, as clinically representative as possible. Emerging as a promising approach for cancer management, targeted radionuclide theranostics (TRT) uses radiotracers to deliver (cytotoxic) radionuclides specifically to cancer cells. Since the field is relatively new, more advanced preclinical models are not yet regularly applied in TRT research. This narrative review examines the currently applied in vitro, ex vivo and in vivo models for oncological research, discusses if and how these models are now applied for TRT studies, and whether not yet applied models can be of benefit for the field. A selection of different models is discussed, ranging from in vitro two-dimensional (2D) and three-dimensional (3D) cell models, including spheroids, organoids and tissue slice cultures, to in vivo mouse cancer models, such as cellline-derived models, patient-derived xenograft models and humanized models. Each of the models has advantages and limitations for studying human cancer biology, radiopharmaceutical assessment and treatment efficacy. Overall, there is a need to apply more advanced models in TRT research that better address specific TRT phenomena, such as crossfire and abscopal effects, to enhance the clinical relevance and effectiveness of preclinical TRT evaluations.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Education
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure if the website is profiting.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Link.springer.com could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {🔍}

models, cell, cancer, pubmed, article, google, scholar, cas, cells, tumour, model, therapy, research, studies, mice, central, tumours, imaging, trt, mouse, vivo, spheroids, lines, culture, human, vitro, targeted, radiotracers, response, cultures, humanized, radionuclide, preclinical, organoids, radiotracer, study, immune, tissue, effects, expression, therapeutic, uptake, med, including, compared, tme, treatment, development, effect, microfluidic,

Topics {✒️}

gov/news-events/press-announcements/fda-approves grpr-targeted radiotracer [177lu]lu-dota-sp714 grpr-targeting radiotracer [177lu]lu-dota-sp714 pd-1-targeted radiotracer [89zr]zr-anti–hpd-1 p53-mediated radiosensitization of177lu-dotatate higher [177lu]lu-dota-sp714 targeting radiotracer [177lu]lu-eb-rgd patient-specific single-domain antibodies lutetium-177-labeled psma-specific tracers prostate-specific membrane antigen targeted radiotracer [68ga]ga-psma-11 article download pdf [89zr]zr-anti–hpd-1 gastrin-releasing peptide receptor egg test-chorioallantoic membrane anti-hpd-l1 tumour uptake patient-derived xenograft models conventional/nanomaterial-based theranostics evaluation gov/drugsatfda_docs/appletter/2016/208547orig1s000ltr gov/drugsatfda_docs/appletter/2018/208700orig1s000ltr gov/drugsatfda_docs/appletter/2022/215833orig1s000ltr patient-derived xenograft cryopreservation 2 mbq [177lu]lu-psma genetically-modified cell lines double-strand dna breaks including [68ga]ga-dotatate modifying epithelial-mesenchymal transition anti-idiotypic radionuclide therapy cell line-derived tumours patient-derived cell model [177lu]lu-psma-617 performed pd-l1 microspect/ct imaging carbon-ion beam irradiation psma-binding ligand212pb-ng001 chick chorioallantoic membrane targeted α-particle therapy nras-mutant melanoma models continuous long-term culture patient-derived cancer organoids [68ga]nodaga-rgdyk uptake abnormal protein localisation/accumulation vivo nras-mutated melanoma tissue-derived primary cells [177lu]lu-psma [177lu]lu-psma-617 patient-derived tumour tissues pd-1-expressing t-cells patient-derived meningioma spheroids genetic/molecular tumour profiles chorioallantoic membrane model

Questions {❓}

Can current preclinical strategies for radiopharmaceutical development meet the needs of targeted alpha therapy?
In vitro methodologies to evaluate nanocarriers for cancer treatment: where are we?
What is the role of the bystander response in radionuclide therapies?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Exploring the landscape of current in vitro and in vivo models and their relevance for targeted radionuclide theranostics
         description:Cancer remains a leading cause of mortality globally, driving ongoing research into innovative treatment strategies. Preclinical research forms the base for developing these novel treatments, using both in vitro and in vivo model systems that are, ideally, as clinically representative as possible. Emerging as a promising approach for cancer management, targeted radionuclide theranostics (TRT) uses radiotracers to deliver (cytotoxic) radionuclides specifically to cancer cells. Since the field is relatively new, more advanced preclinical models are not yet regularly applied in TRT research. This narrative review examines the currently applied in vitro, ex vivo and in vivo models for oncological research, discusses if and how these models are now applied for TRT studies, and whether not yet applied models can be of benefit for the field. A selection of different models is discussed, ranging from in vitro two-dimensional (2D) and three-dimensional (3D) cell models, including spheroids, organoids and tissue slice cultures, to in vivo mouse cancer models, such as cellline-derived models, patient-derived xenograft models and humanized models. Each of the models has advantages and limitations for studying human cancer biology, radiopharmaceutical assessment and treatment efficacy. Overall, there is a need to apply more advanced models in TRT research that better address specific TRT phenomena, such as crossfire and abscopal effects, to enhance the clinical relevance and effectiveness of preclinical TRT evaluations.
         datePublished:2025-02-28T00:00:00Z
         dateModified:2025-02-28T00:00:00Z
         pageStart:3291
         pageEnd:3311
         license:http://creativecommons.org/licenses/by/4.0/
         sameAs:https://doi.org/10.1007/s00259-025-07123-3
         keywords:
            Targeted radionuclide theranostics
            In vitro models
            In vivo models
            Preclinical research
            Cancer
            Nuclear Medicine
            Imaging / Radiology
            Orthopedics
            Cardiology
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00259-025-07123-3/MediaObjects/259_2025_7123_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00259-025-07123-3/MediaObjects/259_2025_7123_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00259-025-07123-3/MediaObjects/259_2025_7123_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00259-025-07123-3/MediaObjects/259_2025_7123_Fig4_HTML.png
         isPartOf:
            name:European Journal of Nuclear Medicine and Molecular Imaging
            issn:
               1619-7089
               1619-7070
            volumeNumber:52
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Berlin Heidelberg
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Lisa Bokhout
               url:http://orcid.org/0009-0003-4640-1395
               affiliation:
                     name:Erasmus MC
                     address:
                        name:Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Joana D. Campeiro
               url:http://orcid.org/0000-0002-2401-1113
               affiliation:
                     name:Erasmus MC
                     address:
                        name:Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Simone U. Dalm
               url:http://orcid.org/0000-0002-6393-6901
               affiliation:
                     name:Erasmus MC
                     address:
                        name:Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Exploring the landscape of current in vitro and in vivo models and their relevance for targeted radionuclide theranostics
      description:Cancer remains a leading cause of mortality globally, driving ongoing research into innovative treatment strategies. Preclinical research forms the base for developing these novel treatments, using both in vitro and in vivo model systems that are, ideally, as clinically representative as possible. Emerging as a promising approach for cancer management, targeted radionuclide theranostics (TRT) uses radiotracers to deliver (cytotoxic) radionuclides specifically to cancer cells. Since the field is relatively new, more advanced preclinical models are not yet regularly applied in TRT research. This narrative review examines the currently applied in vitro, ex vivo and in vivo models for oncological research, discusses if and how these models are now applied for TRT studies, and whether not yet applied models can be of benefit for the field. A selection of different models is discussed, ranging from in vitro two-dimensional (2D) and three-dimensional (3D) cell models, including spheroids, organoids and tissue slice cultures, to in vivo mouse cancer models, such as cellline-derived models, patient-derived xenograft models and humanized models. Each of the models has advantages and limitations for studying human cancer biology, radiopharmaceutical assessment and treatment efficacy. Overall, there is a need to apply more advanced models in TRT research that better address specific TRT phenomena, such as crossfire and abscopal effects, to enhance the clinical relevance and effectiveness of preclinical TRT evaluations.
      datePublished:2025-02-28T00:00:00Z
      dateModified:2025-02-28T00:00:00Z
      pageStart:3291
      pageEnd:3311
      license:http://creativecommons.org/licenses/by/4.0/
      sameAs:https://doi.org/10.1007/s00259-025-07123-3
      keywords:
         Targeted radionuclide theranostics
         In vitro models
         In vivo models
         Preclinical research
         Cancer
         Nuclear Medicine
         Imaging / Radiology
         Orthopedics
         Cardiology
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00259-025-07123-3/MediaObjects/259_2025_7123_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00259-025-07123-3/MediaObjects/259_2025_7123_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00259-025-07123-3/MediaObjects/259_2025_7123_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00259-025-07123-3/MediaObjects/259_2025_7123_Fig4_HTML.png
      isPartOf:
         name:European Journal of Nuclear Medicine and Molecular Imaging
         issn:
            1619-7089
            1619-7070
         volumeNumber:52
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Berlin Heidelberg
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Lisa Bokhout
            url:http://orcid.org/0009-0003-4640-1395
            affiliation:
                  name:Erasmus MC
                  address:
                     name:Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Joana D. Campeiro
            url:http://orcid.org/0000-0002-2401-1113
            affiliation:
                  name:Erasmus MC
                  address:
                     name:Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Simone U. Dalm
            url:http://orcid.org/0000-0002-6393-6901
            affiliation:
                  name:Erasmus MC
                  address:
                     name:Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:European Journal of Nuclear Medicine and Molecular Imaging
      issn:
         1619-7089
         1619-7070
      volumeNumber:52
Organization:
      name:Springer Berlin Heidelberg
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Erasmus MC
      address:
         name:Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
         type:PostalAddress
      name:Erasmus MC
      address:
         name:Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
         type:PostalAddress
      name:Erasmus MC
      address:
         name:Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Lisa Bokhout
      url:http://orcid.org/0009-0003-4640-1395
      affiliation:
            name:Erasmus MC
            address:
               name:Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
               type:PostalAddress
            type:Organization
      name:Joana D. Campeiro
      url:http://orcid.org/0000-0002-2401-1113
      affiliation:
            name:Erasmus MC
            address:
               name:Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
               type:PostalAddress
            type:Organization
      name:Simone U. Dalm
      url:http://orcid.org/0000-0002-6393-6901
      affiliation:
            name:Erasmus MC
            address:
               name:Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
      name:Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
      name:Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands

External Links {🔗}(548)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.56s.

LINK . SPRINGER . COM {}